DENVER, CO--(Marketwired - Jul 9, 2014) - MusclePharm Corporation (OTCQB: MSLP), a scientifically driven, performance-lifestyle sports nutrition company, today announced that Nutrition Journal, an international publication, published the results of a double-blind placebo-controlled clinical study, which demonstrated that MusclePharm's recovery and hydration supplement Amino1 enhanced rehydration more effectively than water and Gatorade.

In this study, recreationally active men and women were dehydrated, and then given three separate rehydration beverages with equal volumes of Amino1, Gatorade or flavored water. The study showed that Amino1 rehydrated individuals significantly faster and more efficiently than Gatorade or water. After consuming Amino1, the test subjects returned to their normal hydration levels in four hours.

"The study showed that consuming both the amino acids and the electrolytes which are in the Amino1 product enhanced rehydration compared to water or Gatorade. The latter primarily containing sugars and electrolytes," MusclePharm Research Director Dr. Jordan Moon said. "As anticipated, water, Gatorade and Amino1 all rehydrated the subjects. However, Amino1 allowed the subjects to rehydrate faster and more efficiently. In the near future, more clinical data will be available that will show the recovery benefits athletes receive when taking Amino1."

The results of this study suggest that taking Amino1 can enhance and facilitate normal rehydration, allowing athletes to recover faster, and also help to maintain normal hydration levels during training or competition. Independent of the re-hydration results, the amino acids in Amino1 have been shown to help muscles recover from exercise, as well as prevent muscle breakdown during exercise, making Amino1 an ideal product for athletes to drink before, during, or after their workouts.

The paper, "An amino acid-electrolyte beverage may increase cellular rehydration relative to carbohydrate-electrolyte and flavored water beverages," is available online at

"Our team of doctors and researchers continue to set the bar for the sports world and performance-based nutritional products," said Brad Pyatt, Chairman and CEO of MusclePharm. "We believe Amino1 is the next evolution in sports drinks and offers athletes the most complete hydration and recovery beverage on the market. We continue our mission of empowering athletes and fueling sports worldwide. We plan to launch our ready-to-drink version of Amino1 in early 2015, which will provide our athletes and consumers more convenience."

About MusclePharm's Amino1
Amino1™ is an award winning clinically proven hydration formula specifically formulated for athletes of all ages and levels of competition. Amino1 is clinically proven to improve hydration faster than other leading sports drinks. The unique combination of amino acids, BCAA's and a complete electrolyte balance with Coconut Water helps fuel max performance and endurance. With zero sugar and only 5 calories, Amino1 is the ultimate Athletes Cocktail™, the most advanced sports drink to hit the market.

About MusclePharm
MusclePharm® is a scientifically driven, performance-lifestyle company that currently develops, manufactures, markets and distributes branded nutritional supplements. The company offers a complete range of powders, capsules, tablets and gels. Its portfolio of recognized brands, including MusclePharm® Hybrid and Core Series, Arnold Schwarzenegger Series™ and FitMiss®, are marketed and sold in more than 110 countries and available in over 35,000 retail outlets globally. These clinically-proven and scientific nutritional supplements are developed through a six-stage research process utilizing the expertise of leading nutritional scientists, doctors and universities. MusclePharm is the innovator of the sports nutrition industry. For more information, visit

Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.